Top Markets
#1 Black Phoenix Black Phoenix +165.81%
#2 Islamic Coin Islamic Coin +158.09%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +25.47%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +19.43%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.69%
#8 Test Test +15.09%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.31%
#10 DOVU DOVU +9.07%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Comera Life Sciences Holdings, Inc. Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc.

CMRAW
Rank in Stocks #41593
Comera Life Sciences Holdings, Inc. is an early-stage life sciences company... Comera Life Sciences Holdings, Inc. is an early-stage life sciences company dedicated to developing its own innovative therapeutics. These treatments leverage its unique SQore formulation platform, which is engineered to convert biologics typically administered intravenously (IV) into convenient subcutaneous (SQ) versions. The company's pipeline currently features two primary drug candidates: CLS-001, an improved biologic in preclinical development, targets Crohn's and Ulcerative Colitis; and CLS-002, also in preclinical stages, is an enhanced biologic aimed at various oncological indications. Established in 2014, Comera Life Sciences is based in Woburn, Massachusetts.
Share Price
$0.0008
Last synced: 2024-03-14
Market Cap
$15.27K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Comera Life Sciences Holdings, Inc. (CMRAW)

Category

Healthcare
Revenue for Comera Life Sciences Holdings, Inc. (CMRAW)
Revenue in Aug 2026 TTM: 0
According to Comera Life Sciences Holdings, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Comera Life Sciences Holdings, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR